— Published date: 9/12/2025 Value Proposition: Wireless device that offers a range of motion biofeedback to patients undergoing hand therapy. Technology Description Researchers at Washington University in St. Louis have developed a device designed to provide continuous, real-time kinematic biofee…

— Published Date: 8/8/2025 Value Proposition: Computational method that uses placental ultrasound images to detect prenatal and placental conditions early. Technology Description Researchers at Washington University in St. Louis have developed a computational method that predicts fetal conditions …

— Published Date: 6/18/2025 Value Proposition: Software tool that uses a novel denoising method to remove electrical stimulation artifacts from electrophysiology data while preserving physiological signals. Technology Description Researchers at Washington University in St. Louis have developed …

— Published Date: 6/18/2025 Value Proposition: Non-sweeping, steerable guide for laser probes used in thermo-ablative systems to improve treatment of brain tumors. Technology Description Researchers at Washington University in St. Louis have developed a steerable device that can be integrated i…

— Published Date: 6/12/2025 Value Proposition: Endovascular ventricular device that improves blood flow at lower rotational speed. Technology Description Researchers at Washington University in St. Louis have developed a toroidal endovascular ventricular support device (TEVAD) that is design…

— Published Date: 6/3/2025 Value Proposition: System that employs gut microbe strains engineered with therapeutic enzymes to treat chronic gut conditions. Technology Description Researchers at Washington University in St. Louis have developed a hypervesiculating Bacteroides theatiotaomicron (Bt) …

— Published Date: 5/13/2025 Value Proposition: An innovative therapy leveraging unique chimeric antigen receptors (CAR) to specifically target Fc receptor-like 5 (FCRL5), enabling the precise elimination of FCRL5-expressing cells to treat multiple myeloma and other cancers. Technology Description …

— Published Date: 5/14/2025 Value Proposition: Novel antisense oligonucleotide (ASO) directly targeting a microRNA-mediated mechanism responsible for autophagy reduction and neurodegeneration in Huntington’s disease (HD) improving patient outcomes in pre-HD subjects. Technology Description R…

— Published Date: 5/14/2025 Value Proposition: Robust and reliable biomarker to accurately predict patient response to PARP inhibitors and platinum chemotherapy for high grade serous ovarian cancer. Technology Description Researchers at Washington University in St. Louis have developed an automat…

— Published Date: 5/14/2025 Value proposition: Self-sustaining chimeric macrophages as a novel approach to target amyloid plaques resulting in improved efficacy and survival in patients. Technology Description Researchers from Washington University in St. Louis have engineered macrophages to expre…

— Published Date: 5/14/2025 Value proposition: Using CAR T-cells to treat Alzheimer’s disease and other neurodegenerative diseases through Ab-specific activation. Technology Description While CD4+ (helper or effector) T-cells play complex roles in the pathophysiology of Alzheimer’s …

— Published Date: 5/14/2025 Value proposition: Novel ASOs that increase key protein production to limit neurodegeneration caused by ALS and frontotemporal dementia (FTD). Technology Description TDP-43 pathology is present in ~97% of ALS, ~50% of FTD, and frequently observed in other neurodegenerat…

— Published Date: 5/15/2025 Value proposition: Novel analgesic compounds that block CaV3.2 currents in nociceptive dorsal root ganglion neurons in order preemptively treat pain in subjects, unlike other products that are continuously administered post onset of pain. Technology Description Resear…

— Published Date: 5/14/2025 Value Proposition: Method that uses gene-therapy to detect limb-girdle muscular dystrophy (LGMD) type 4R/2E. Technology Description Researchers at Washington University in St. Louis have developed a method of predicting limb-girdle muscular dystrophy (LGMD) type 4R/2…

— Published Date: 12/21/24 Value proposition: A cost-effective, drug-based therapy targeting the endothelin B receptor (ETBR) to promote peripheral nerve regeneration, offering improved recovery and compatibility with existing treatments. Technology Description Researchers at Washington University…

— Published Date: 5/13/2025 Value Proposition: Plasma cell-free transcripts that can be used as biomarkers to aid in the diagnosis and monitoring of Parkinsons Disease. Technology Description Researchers at Washington University in St. Louis have developed a panel of cell free RNA (cfRNA) biomark…

— Published Date: 5/13/2025 Value Proposition: A novel approach to repurposing FDA-approved anti-epileptic drugs to treat brain and nerve tumors associated with neurofibromatosis type I, offering a faster, cost-effective pathway to address an urgent unmet medical need. Technology Description Neuro…

— Published Date: 5/13/2025 Value Proposition: Promotion of recovery and reduction of neuronal damage following nerve injury, first T cell approach to neurological disorders. Technology Description Traumatic injuries to the spinal cord or the brain currently have limited treatment options, particu…

— Published Date: 5/13/2025 Value proposition: New therapeutic modality that uses CNS self-peptides to treat autoimmune diseases, reducing neuroinflammation damage in an organ-specific manner. Technology Description Autoimmune diseases continue to debilitate countless individuals, increasing healt…

— Published Date: 12/24/2024 Value proposition: An advanced CAR-T cell therapy engineered to reduce T cell exhaustion, enhancing durability and effectiveness in cancer treatment by overcoming one of the leading causes of long-term treatment failure. Technology Description Researchers at Washington…